23
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Clinical and Preclinical Pharmacology of Liposomal Vincristine

, , , , , & show all
Pages 501-512 | Published online: 28 Sep 2008

References

  • Shipp M. A., Mauch P. M., Harris N. L. Non-Hodgkin's lymphomas in Cancer. Principles and practices of oncology, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 2165–2220
  • Rowinsky E. K., Donehower R. C. Antimicrotubule agents in Cancer. Principles and practices of oncology, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 467–483
  • Boman N. L., Bally M. B., Cullis P. R., Mayer L. D., Webb M. S. Encapsulation of vincristine in liposomes reduces its toxicity and improves its anti-tumor efficacy. J. Liposome Res. 1995; 5: 523–541
  • Mayer L. D., Gelmon K., Cullis P. R., Boman N., Webb M. S., Embree L., Tolcher T., Bally M. B. Preclinical and clinical studies with liposomal vincristine. Progress in Drug Delivery Systems IV. Biomedical Research Foundation, Tokyo 1995; 151–161
  • Jackson D. V., Jr., Sethi V. S., Pharm M., Spurr C. L., Willard V., White D. R., Richards F., Stuart J. J., Muss H. B., Cooper M. R., Homesley H. D., Jobson V. W., Castle M. C. Intravenous vincristine infusion: Phase 1 trial. Cancer 1981; 48: 2559–2564
  • Jackson D. V., Jr., Paschold E. H., Spurr C. L., Muss H. B., Richards F., II, Cooper M. R., White D. R., Stuart J. J., Hopkins J. O., Rich R., Jr., Wells H. B. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 1984; 53: 2601–2606
  • DeVita V. T., Jr., Mauch P. M., Harris N. L. Hodgkin's disease in Cancer. Principles and practices of oncology, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 2242–2283
  • Salmon S. E., Cassady J. R. Plasma cell neoplasms in Cancer. Principles and practices of oncology, V. T. DeVita, Jr., S. Hellman, S. A. Rosenberg. Lippincott-Raven, Philadelphia 1997; 2344–2387
  • Bally M. B., Lim H., Cullis P. R., Mayer L. D. Controlling the drug delivery attributes of lipid-based drug formulations. J. Liposome Res. 1998; 8: 299–335
  • Wu N. Z., Da D., Rudoll T. L., Needham D., Whorton A. R., Dewhirst M. W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 1993; 53: 3765–3770
  • Cullis P. R., Hope M. J., Bally M. B., Madden T. D., Mayer L. D., Fenske D. B. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim. Biophys. Acta 1997; 1331: 187–211
  • Webb M. S., Harasym T. O., Masin D., Bally M. B., Mayer L. D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 1995; 72: 896–904
  • Boman N. L., Mayer L. D., Cullis P. R. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta 1993; 1152: 253–258
  • Boman N. L., Masin D., Mayer L. D., Cullis P. R., Bally M. B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994; 54: 2830–2833
  • Boman N. L., Cullis P. R., Mayer L. D., Bally M. B., Webb M. S. Liposomal vincristine: The central role of drug retention in defining therapeutically optimized anticancer formulations. Long circulating liposomes: old drugs, new therapeutics, M. C. Woodle, G. Storm. Landes Bioscience, Georgetown, Texas 1997; 29–49
  • Gelmon K. A., Tolcher A., Diab A. R., Bally M. B., Embree L., Hudon N., Dedhar C., Ayers D., Eisen A., Melosky B., Burge C., Logan P., Mayer L. D. Phase I study of liposomal vincristine. J. Clin. Oncol. 1999; 17: 697–705
  • Embree L., Gelmon K., Tolcher A., Hudon N., Heggie J., Dedhar C., Logan P., Bally M. B., Mayer L. D. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother. Pharmacol. 1998; 41: 347–352
  • Sarris A. H., Romaguera J., Hagemeister F., Rodriguez M. A., McLaughlin P., Dang N., Tsimberidou A. M., Medeiros L. J., Samuels B., Oholendt M., Pate O., Burge C., Cabanillas F. Liposomal vincristine: a Phase II trial in relapsed or refractory non-Hodgkin's lymphomas (NHL). Blood 1999; 94: 94a, (Suppl. 1)
  • Sarris A. H., Hagemeister F., Romaguera J., Rodriguez M. A., McLaughlin P., Tsimberidou A. M., Medeiros L. J., Samuels B., Pate O., Oholendt M., Kantarjian H., Burge C., Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Annals of Oncology 2000; 11: 69–72

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.